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Adrenergic modulation of extrarenal potassium in men with end-stage
renal disease. In normal subjects, beta-adrenergic stimulation lowers the
serum potassium, whereas alpha-stimulation raises it. Epinephrine, a
mixed alpha and beta agonist, acutely lowers the blood potassium in
normal subjects, but not in patients with end-stage renal disease. This
study was designed to determine whether the resistance to the hypo-
kalemic effect of epinephrine in dialysis patients is due to a blunted
beta-adrenergic response, or to an augmented alpha-adrenergic re-
sponse. The infusion of epinephrine at low doses (0.01 Wkg/min)
produced a significant increase in serum potassium in hemodialysis
patients (+0.21 0.07 mmol/liter, P < 0.05), as compared to a
nonsignificant decrease (—0.06 0.04 mmol/liter) in normal subjects.
Epinephrine at high physiologic doses (0.04 sgIkg/min) failed to signif-
icantly change the serum potassium in the dialysis patients (—0.10
0.14 mmollliter), but substantially lowered serum potassium in the
controls (—0.64 0.10 mmol/liter, P < 0.001). There was no significant
correlation (r = 0.03) between the baseline serum potassium concen-
tration and the magnitude of change during epinephrine infusion.
Epinephrine infusion (0.04 gIkg/min) during beta-blockade with pro-
pranolol produced a greater rise in serum potassium in the dialysis
patients as compared to the controls (+0.69 0.11 vs. +0.32 0.11
mmol/liter, P < 0.05). Epinephrine infusion (0.01 sg/kg/min) during
alpha-blockade with phentolamine resulted in similar changes in serum
potassium in dialysis patients and in normal control (—0.10 0.12 vs.
—0.10 0.06 mmol/liter). Moreover, phentolamine reversed the in-
crease in serum potassium observed in dialysis patients during the
infusion of epinephrine following beta-blockade. These results suggest
that hemodialysis patients have an impaired extrarenal clearance of
potassium in response to epinephrine, that is attributable to an en-
hanced hyperkalemic response to alpha-adrenergic stimulation.
The kidneys play a major role in the excretion of dietary
potassium [1]. Since patients with end-stage renal disease have
an impaired ability to excrete potassium, they are very suscep-
tible to developing hyperkalemia. Thus, transcellular shifts of
potassium from the extracellular to the intracellular compart-
ments assume a critical role in the defense against hyperkalemia
in these patients. Previous investigations have suggested an
important role for catecholamines in stimulating transcellular
potassium shifts in normal individuals [1—61. The infusion of
physiologic doses of epinephrine acutely lowers the serum
potassium concentration, and attenuates the hyperkalemic re-
Received for publication March 22, 1991
and in revised form July 9, 1991
Accepted for publication July Il, 1991
© 1991 by the International Society of Nephrology
sponse to infused potassium in subjects with normal renal
function [7]. Several lines of evidence suggest that this hypo-
kalemic effect is mediated by beta-2 receptors. The administra-
tion of selective beta-2 antagonists or nonselective beta block-
ers prevents the hypokalemic effect of epinephrine [3, 5, 61,
whereas beta-l blockers do not prevent this effect [61. More-
over, selective beta-2 agonists, such as albuterol, lower blood
potassium in normal subjects [8—10].
The beta-2 agonist, albuterol, in both the intravenous and
nebulized forms, has a significant potassium-lowering effect in
hemodialysis patients [11—14]. In contrast, the hypokalemic
response to intravenous epinephrine is absent or blunted in
these patients [15—171. The reason for the discrepancy has not
been previously addressed. Since epinephrine is a mixed alpha-
and beta-agonist, the net effect of infused epinephrine on
plasma potassium will depend on the relative balance between
alpha and beta-2 agonist effects. Alpha adrenergic stimulation
has the opposite effect of beta-2 stimulation on extrarenal
potassium disposal: it causes potassium to shift from the
intracellular to the extracellular compartment [181. Conversely,
alpha blockers have been reported to decrease the hyperkale-
mic response to an intravenous potassium load or to exercise in
normal subjects [18, 19].
Thus, the resistance to the hypokalemic effect of epinephrine
in patients with end-stage renal disease could be due either to a
diminished beta-2 responsiveness or to an enhanced alpha-
adrenergic responsiveness. The purpose of this study was to
clarify which mechanism is responsible for the resistance to the
hypokalemic effect of epinephrine in hemodialysis patients.
This question was addressed by evaluating the changes in
serum potassium concentration in hemodialysis patients and in
normal controls during a graded epinephrine infusion, in the
absence or presence of beta-adrenergic blockade with propran-
olol or alpha blockade with phentolamine.
Methods
Subjects
Eight maintenance hemodialysis patients and seven normal
controls were studied. The hemodialysis patients were derived
from the outpatient dialysis units of the University of Alabama
at Birmingham and the Veterans Administration Hospital in
Birmingham. The controls were general medical patients fol-
lowed in the outpatient clinics who had normal renal function
(serum creatinine concentration < 150 mol/liter). Exclusion
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criteria for all subjects included: presence of diabetes, asthma,
heart failure, angina, or unstable heart rhythm; hematocrit
below 0.25; medication with digitalis, converting enzyme inhib-
itors, prostaglandin synthetase inhibitors, beta blockers or
alpha blockers. Seven of the eight hemodialysis patients and all
the controls were men. The mean age of the dialysis patients
was 48 3 years (range, 37 to 60), and the mean age of the
controls was 36 4 years (range, 26 to 52).
Each subject provided informed consent for participation in
the protocol approved by the University of Alabama at Bir-
mingham Institutional Review Board. All subjects were studied
in the fasting state. Hemodialysis patients were studied imme-
diately preceding their next scheduled dialysis treatment. All
the experiments were performed on an outpatient basis with
continuous cardiac monitoring. There were five experimental
protocols.
Protocol 1: Effect of a graded epinephrine infusion on serum
potassium concentration
Indwelling intravenous lines were placed in one arm for
infusion of drugs, and in the contralateral arm for blood
sampling. During a 30-minute control period, 0.45% saline was
infused at 1.0 mllmin. Three consecutive blood samples and
measurements of blood pressure and heart rate were obtained at
10 minute intervals. An intravenous infusion of epinephrine in
0.45% saline was then started. It was maintained at 0.01
g/kg/min for 45 minutes, then increased to 0.02 g/kg/min for
45 minutes, and finally to 0,04 g/kg/min for 45 minutes. Doses
in this range produce plasma epinephrine concentrations com-
parable to physiologic levels measured during stress [7J. Blood
collections and measurements of vital signs were performed at
15 minute intervals throughout the 135 minute experimental
phase. The subjects were monitored closely for symptoms and
cardiac arrhythmias.
Protocol 2: Effect of epinephrine infusion following acute
beta-blockade on serum potassium concentration
The hemodialysis patients and controls were restudied on a
separate day, using a similar protocol except that they were
infused with propranolol, 1.43 g/kg/min, during the 30-minute
control period, in order to produce beta-blockade. This was
followed by an epinephrine infusion protocol identical to that
followed in the first experiment.
Protocol 3: Effect of epinephrine infusion following acute
alpha-blockade on serum potassium concentration
Four of the hemodialysis patients and four of the controls
were restudied under this protocol. After receiving a 30 minute
infusion of phentolamine at 0.5 mg/mm, an infusion of epineph-
rifle at 0.01 g/kg/min was given over 45 minutes, superimposed
on continued phentolamine administration. (The phentolamine
was a gift of CIBA-GEIGY Pharmaceuticals). In the initial two
experiments with dialysis patients higher doses of epinephrine
were attempted. However, the combination of phentolamine
and higher doses of epinephrine resulted in profound hypoten-
sion (>40 mm Hg decrease in blood pressure), necessitating
discontinuation of the experiment. Therefore, all subsequent
studies in this protocol utilized only the lowest dose of epineph-
rine.
Protocol 4: Effect of alpha-blockade on serum potassium
concentrations in patients receiving a beta-blocker and an
epinephrine infusion
To evaluate whether the effect of epinephrine during beta-
blockade could be reversed by alpha-blockade, four of the
hemodialysis patients were restudied. They were initially in-
fused with propranolol, 1.43 g/kgImin, during a 30-minute
control period, in order to produce beta blockade. This was
followed by a 90 minute infusion of epinephrine at 0.01 gIkgI
mm. During the last 45 minutes of the epinephrine infusion,
they received a simultaneous infusion of the alpha-blocker,
phentolamine, 0.5 mglmin.
Protocol 5: Effect of epinephrine on serum potassium
concentration during simultaneous alpha- and beta-blockade
To ensure that the doses of propranolol and phentolamine
used in the previous protocols totally abolished the effect of
epinephrine on serum potassium, three normal controls were
studied under this protocol. They received an initial 30 minute
infusion of phentolamine, 0.5 mg/mm, and propranolol, 1.43
j.tglkglmin. Then epinephrine was infused for 45 minutes at 0.04
g/kg/min, superimposed on continued administration of phen-
tolamine.
Analytic methods
All blood samples were promptly centrifuged, and the serum
assayed for potassium concentration, using a flame photometer.
The remaining aliquots were frozen, and subsequently assayed
for glucose, phosphate, and insulin. Glucose and phosphate
were measured colorimetrically and insulin by radioimmunoas-
say.
Statistical procedures
The baseline value for each variable was calculated from the
mean of the three measurements during the control period. All
values were expressed as means SE. The effect of epinephrine
at each dose level was calculated from the difference between
the value of the variable during the infusion and the baseline
value. Since the effects of epinephrine at each dose achieved a
plateau within 30 minutes, the effect of that dose was calculated
from the mean of the two measurements obtained at 30 and 45
minutes after starting that infusion rate. The alpha-adrenergic
effect of epinephrine was taken as the value measured during
beta-blockade with propranolol. The beta-adrenergic effect of
epinephrine was calculated from the difference between the
effect measured during epinephrine infusion in the absence of
beta-blockade and the effect measured during epinephrine infu-
sion after propranolol pretreatment. The beta-effect was also
estimated from the effect of epinephrine infusion during alpha-
blockade with phentolamine. The overall effect of epinephrine
on changes in serum potassium, glucose, and insulin was
evaluated by one-way analysis of variance, whereas the signif-
icance of the differences in the effects on the two subject
populations was tested by two-way analysis of variance. Dif-
ferences at individual dose levels of epinephrine were compared
by Student t-tests. A P value less than 0.05 was considered
statistically significant.
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The baseline serum potassium concentration before starting
the epinephrine infusion was significantly higher in the end-
stage renal disease patients, as compared to the control subjects
(4.84 0.44 vs. 3.95 0.08 mmol/liter, P < 0.001). The
administration of epinephrine to normal controls produced a
dose-dependent decrease in serum potassium, with a slight
decrease (—0.06 0.04 mmol/liter) observed at the lowest dose
(0.01 sg/kgImin), and a substantial decrease of 0.64 0.10
mmollliter (P < 0.001) at the highest infusion rate (0.04 sg/kg/
mm; Fig. 1, upper panel). In contrast, the lowest dose of
epinephrine actually produced a significant increase (+0.21
0.07 mmol/liter, P <0.05) in the potassium concentration in the
dialysis patients. Even at the highest dose of epinephrine, the
serum potassium concentration failed to decrease significantly
in the patients with end-stage renal disease (—0.10 0.14
mmollliter).
There was no significant correlation between the baseline
serum potassium concentration and the magnitude of change
during the infusion of epinephrine at the highest rate (r = 0.03).
Five of the dialysis patients studied had baseline serum potas-
sium concentrations in the normal range (values between 3.79
and 4.49 mmollliter). The mean maximal change in potassium
concentrations for this subgroup was —0.10 0.11 mmol/liter,
significantly different from the change observed in the control
group (P < 0.001). There was also no significant correlation (r=
0.15) between patient age and change in serum potassium in the
dialysis patients.
The baseline serum potassium concentrations at the begin-
ning of the second study were similar to those measured prior to
the first study (4.71 0.26 and 3.86 0.16 mmol/liter in the
hemodialysis patients and the normal subjects, respectively).
During the 30-minute propranolol infusion in the control period
there was no significant change in the serum potassium concen-
tration in either the hemodialysis patients or in the control
subjects. The infusion of epinephrine following beta-blockade
resulted in a dose-dependent increase in serum potassium in
both the hemodialysis patients (P < 0.01) and in the normals (P
< 0.05; Fig. 1, middle panel). The magnitude of this increase
was greater in the end-stage renal disease patients, as compared
to the controls (0.69 0.11 vs. 0.32 0.11 mmol/liter, P < 0.05,
at the highest infusion dose).
To calculate the effect of the beta-adrenergic component of
epinephrine on serum potassium at each dose level, the change
in serum potassium during epinephrine infusion with beta
blockade was subtracted from the change in potassium during
epinephrine infusion without beta-blockade. The calculated
beta-adrenergic effect of epinephrine resulted in a significant (P
<0.001) hypokalemic effect in both experimental groups (Fig.
1, lower panel). The magnitude of the hypokalemic effect did
not differ significantly between the hemodialysis patients and
the normal controls. At the highest infusion rate of epinephrine
the calculated beta-adrenergic effect of epinephrine on serum
potassium concentration was —0.82 0.15 mmol/liter in the
dialysis patients, and —0.96 0.18 mmol/liter in the subjects
with normal renal function.
As further confirmation of these results the effect of alpha-
blockade during epinephrine infusion at 0.01 sg/kg/min was
evaluated in a subset of four dialysis patients and four normal
Dose of epinephrine, p.g/kglmin
Fig. 1. Changes in serum potassium concentration (means SE) from
baseline during the infusion of intravenous epinephrine at 3 doses in
hemodialysis patients (solid bars) and normal controls (hatched bars).
A. The effect of epinephrine alone (alpha plus beta adrenergic stimula-
tion). B. The effect of epinephrine during beta blockade (pure alpha
effect). C. The calculated pure beta effect.
controls. During epinephrine infusion alone, the serum potas-
sium tended to increase in the dialysis patients and to decrease
in the controls, with a significant difference between the two
experimental groups (Fig. 2). The change in serum potassium
during epinephrine infusion with prior alpha blockade, as
compared to the change with epinephrine alone, was signifi-
cantly different in the dialysis patients but not in the controls.
Thus, after alpha blockade epinephrine produced a similar
change in serum potassium in both experimental groups.
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Fig. 2. Changes in serum potassium concentration (means SE) from
baseline during the infusion of intravenous epinephrine (0.0/ sg/kgI
mm) in the absence (EPI) or presence of alpha-blockade by phentola-
mine (EPI + PHEN) in hemodialysis patients (solid bars) and normal
controls (hatched bars). * P < 0.05 vs. centrol patients; t P < 0.05 vs.
treatment with epinephrine plus phentoLimine.
Some of the dialysis patients were restudied to determine
whether the effect of epinephrine could be reversed with an
alpha-blocker (Protocol 4). The epinephrine infusion (0.01 g/
kg/miri) following beta-blockade with propranolol produced a
0.39 0.07 mmol/liter increase (P < 0.01) in the serum
potassium concentration (Fig. 3). The superimposition of phen-
tolamine decreased the serum potassium concentration by 0.31
0.07 mmol/liter (P < 0.02) to a level not different from the
baseline.
Epinephrine infusion during combined alpha- and beta-block-
ade did not produce a significant change in serum potassium in
the control subjects studied under this protocol. The mean
serum potassium concentration was 3.70 0.13, 3.76 0.19,
and 3.77 0.18 mmol/liter at baseline after 30 minutes of
infusion of propranolol and phentolamine, and during the
epinephrine infusion, respectively.
The baseline serum glucose concentration prior to the epi-
nephrine infusion was similar in the hemodialysis patients and
in the controls (5.2 0.2 vs. 5.2 0.3 mmol/liter), The infusion
of epinephrine produced a dose-dependent increase in serum
glucose concentration in both groups of subjects (Table 1).
Overall, the magnitude of the increase was smaller in the
dialysis patients as compared to the controls (P <0.05). At the
highest infusion dose the increase in serum glucose concentra-
tion was 1.7 0.4 mmol/liter in the dialysis patients, and 2.9
0.3 mmol/liter in the normal subjects (P 0.05). The baseline
serum glucose concentrations at the beginning of the second
study were similar to the values obtained in the first study (5.0
0.2 vs. 5.1 0.2 mmol/liter in the end-stage renal disease
patients and in the normal subjects, respectively). The hyper-
glycemic effect of epinephrine was not abolished by prior
beta-adrenergic blockade. With propranolol pretreatment, the
increase in serum glucose with the highest epinephrine dose
was 1.3 0.3 mmol/liter in the hemodialysis patients, and 2.3
0.5 mmol/liter in the controls (P 0.10).
Prior to infusion of epinephrine in the first study, the fasting
serum insulin concentrations were similar in the dialysis pa-
tients and in the normal controls (Table 1). There were no
significant changes in the serum insulin concentrations during
the epinephrine infusion in either experimental group. The
baseline insulin concentrations were similar in both experimen-
tal groups at the beginning of the second study (Table 1). The
infusion of epinephrine following beta-blockade produced a
small decrease in plasma insulin concentration in both experi-
mental groups, although this effect did not achieve statistical
+ significance.
The baseline serum phosphate concentration during the con-
trol period of the first study was significantly higher in the
dialysis patients than in the control subjects (2.07 0.37 vs.
1.03 0.07 mmol/liter, P < 0.001). Epinephrine resulted in a
dose-related decrease in serum phosphate levels in the control
subjects, but had no significant effect in the dialysis patients
(Table 1). The change in serum phosphate concentrate was
significantly correlated with the change in serum potassium in
the control subjects (r = 0.76, P <0.05), but not in the dialysis
patients (r = 0.10, P = 0.82). The baseline serum phosphate
concentrations during the control period of the second study
were 2.17 0.23 and 1.10 0.07 mmol/liter (P < 0.005) in the
dialysis patients and control subjects, respectively. Prior beta-
blockade prevented the hypophosphatemic effect of epineph-
rine in the control subjects.
During the control period of the first study the baseline heart
rate was 74 4 and 63 2 min in the dialysis patients and
control subjects, respectively. Epinephrine infusion resulted in
a dose-related increase in heart rate in both the dialysis patients
(P < 0.05) and in the controls (P <0.05). The magnitude of this
rise tended to be lower in the dialysis patients than in the
subjects with normal renal function, although this difference did
not achieve statistical significance. The maximal increase in
heart rate was 9.3 3.0 and 14.0 3.9 min in the dialysis
patients and the controls, respectively.
In the second study, the baseline heart rate was similar in
both groups (77 4 vs. 77 2 min', in the dialysis patients
and the controls, respectively). Propranolol treatment de-
creased the basal heart rate in both groups of subjects, although
the magnitude of this decrease was smaller in the dialysis
patients than in the controls (9.6 1.3 vs. 19.7 2.1 min', P
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Fig. 3. Effect of superimposed epinephrine infusion (0.01 ig/kg/min)
and epinephrine plus phentolamine (0.5 mg/mm) infusion in hemodial-
ysis patients pretreated with the beta-blocker, propranolol. PRO =
propranolol; EPI = epinephrine; PHEN = phentolamine. * P< 0.01 vs.
propranolol alone; t P < 0.02 vs. propranolol plus epinephrine.
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Table 1. Changes in serum glucose, insulin, and phosphate concentrations during the infusion of epinephrine with and without beta-blockade
Epinephrine alone Epinephnne + propranolol
Dialysis patients ControlsDialysis patients Controls
Change in serum glucose mmo//Iiter
Dose of epinephrine p.glkglmin
0.01 0.25 0.15 0.42 0.08 0.42 0.23 0.80 0.30
0.02 0.74 022b 1.33 0.20' 1.17 0.07" 1.17 0.26"
0.04 1.67 0.43" 2.89 Ø34IC 1.28 0.32" 2.33 0.52"
Serum insulin p.UImI
Baseline 12.9 2.2 10.3 1.4 12.1 3.4 7.8 1.3
0.01 11.8 2.0 10.4 1.9 10.6 2.8 6.3 1.0
0.02 13.8 3.1 11.2 1.8 10.0 2.7 6.0 0.7
0.04 15.7 5.0 10.6 1.4 10.0 2.7 6.4 0.8
Change in serum phosphate mmollliter
Dose of epinephrine pglkglmin
0.01 —0.07 0.05 —0.08 Q•Q3C —0.03 0.09 —0.02 0.01
0.02 —0.08 0.04 —0.12 0.04a +0.05 0.05 —0.03 0.03
0.04 —0.10 0.06 —0.15 003b —0.06 0.11 —0.04 0.03
Values represent mean SE.
a P < 0.05 vs. control period.
"P < 0.01 vs. control period.
P < 0.05 vs. the hemodialysis patients.
< 0.002). Following beta-blockade, there was no significant
change in heart rate in either experimental group during epi-
nephrine infusion (maximal increase, 1.3 1.1 and 0.5 1.5
min' in the patients with end-stage renal disease and in the
normal subjects, respectively).
The infusion of epinephrine superimposed on alpha-blockade
with phentolamine produced an increase in heart rate of similar
magnitude in the dialysis patients and in the control subjects
(+23.5 3.9 vs. 28.8 4.8 min', P = 0.29).
The baseline mean blood pressure during the control period
of the first study was higher in the hemodialysis patients as
compared to the controls (110 5 vs. 94 6mm Hg, P < 0.05).
It did not change significantly in either group with the infusion
of epinephrine (+7.1 9.8 and +0.3 4.2 mm Hg in the
dialysis patients and controls, respectively). There were also no
significant changes in the mean blood pressure in either group
during the infusion of epinephrine after beta-blockade (—8.6
9.2 and +3.5 6.7 mm Hg in the dialysis patients and the
controls, respectively). The decrease in mean blood pressure
during the infusion of epinephrine superimposed on alpha
blockade tended to be greater in the dialysis patients, as
compared to the control subjects (—23.8 13.2 vs. —5.0 3.9
mm Hg).
Discussion
The patients with end-stage renal disease had a markedly
blunted hypokalemic response to intravenous epinephrine
(combined alpha- and beta-adrenergic stimulation), and an
enhanced hyperkalemic response to epinephrine infusion during
beta-blockade (pure alpha-adrenergic stimulation). The calcu-
lated beta-adrenergic effect of epinephrine did not differ be-
tween the dialysis patients and the normal controls. Alpha-
blockade prevented the resistance to the hypokalemic effect of
epinephrine. Taken together, these observations suggest that
the resistance to the hypokalemic effect of epinephrine in
hemodialysis patients is primarily due to an increased respon-
siveness to alpha-stimulation, that antagonizes the hypokalemic
effect of beta-stimulation.
The resistance to the hypokalemic effect of epinephrine in
patients with end-stage renal disease is in keeping with previous
reports [15—17]. It is not likely that this resistance was due to a
higher baseline serum potassium concentration, since it was
manifested even in the normokalemic dialysis patients. How-
ever, an increased intracellular load of potassium in the dialysis
patients cannot be ruled out as a contributory factor in their
resistance to the hypokalemic effect of epinephrine. Only two
previous studies have directly compared the effects of epineph-
rifle in hemodialysis patients and in controls. Gifford et al [171
infused physiologic doses (0.015 g/kg/min) and observed an
impaired hypokalemic response in the dialysis patients. In
contrast, Yang et al [20] administered pharmacologic doses
(0.10 j.tg/kg/min) and measured similar decreases in serum
potassium concentrations in both experimental groups. Since
the alpha effect of epinephrine peaks at very low doses,
whereas the beta effect continues to rise at higher doses (Fig. 1),
it is possible that the resistance to the hypokatemic effect of
epinephrine in dialysis patients may be overcome by providing
sufficiently high doses of the drug. The study by Martinez Vea
et al [16] suggests that a subset of dialysis patients may also
have a blunted beta-2 response to the hypokalemic effects of
epinephrine (0.10 g/kg/min).
The effect of epinephrine on serum potassium during beta
blockade was assumed to represent a valid assessment of the
alpha-adrenergic effect. The validity of this assumption depends
both on the adequacy of the beta-blockade by propranolol, as
well as a demonstration that propranolol does not possess a
direct hyperkalemic effect. The former assumption may be
inferred from the abolition of the increase in heart rate with
doses of epinephrine that clearly increased the heart rate in the
first study (epinephrine without propranolol). The latter as-
sumption is supported by the reversal of the hyperkalemic
effect of epinephrine with propranolol by the administration of
the alpha-blocker, phentolamine. We also considered perform-
ing a direct measurement of the effect of a pure alpha-agonist,
such as phenylephrine, on serum potassium. However, in a
previous study the administration of phenylephrine to normal
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subjects had no effect on serum potassium [18]. The discrep-
ancy between the effect of epinephrine with propranolol and the
effect of phenylephrine is likely due to the greater potency of
the former alpha-agonist.
Previous research has demonstrated a similar hypertensive
response to the alpha agonist, norepinephrine, in hypertensive
hemodialysis patients and in normal controls [21, 22]. The
administration of debrisoquine, a postganglionic sympathetic
blocker, resulted in marked decreases in blood pressure in
hypertensive dialysis patients, but did not affect the blood
pressure in normal controls [22]. A similar hypotensive effect
was observed in the present study when dialysis patients were
given phentolamine with epinephrine. These observations sug-
gest that in dialysis patients hypertension, like hyperkalemia, is
strongly dependent on an alpha-adrenergic mechanism.
The current observation of an intact hypokalemic response to
beta-2 adrenergic stimulation is consistent with previous studies
utilizing either intravenous or nebulized albuterol in hemodial-
ysis patients [11—14]. A recent report [101 observed a blunted
hypokalemic response to inhaled albuterol in hemodialysis
patients as compared to subjects with normal renal function.
The latter study would suggest that some patients with end-
stage renal disease may be hyporesponsive to the hypokalemic
effect of beta-2 stimulation, although the systemic absorption of
an inhaled drug may be quite variable. Due to the relatively
small number of subjects enrolled in the present study, one
cannot entirely exclude the possibility of a Type II error (that is,
a significant difference in beta-2 responsiveness between the
two experimental groups that may have been missed). It would
appear from Figure 1, however, that this difference would be of
fairly small magnitude.
The enhanced hyperkalemic effect of alpha-stimulation could
be due either to higher plasma levels of norepinephrine or to
increased sensitivity of the receptors to the effect of epineph-
rine. Plasma levels of epinephrine and norepinephrine were not
measured in the present study. Basal plasma norepinephrine
levels have been reported to be higher in dialysis patients than
in normal controls by Cuche et a! [23], but no significant
difference was found by others [17, 22, 24]. Basal epinephrine
levels were higher in dialysis patients in one study [22], but this
was not confirmed by others [23, 24]. During epinephrine
infusion, epinephrine levels were not different between dialysis
patients and controls; norepinephrine levels tended to be higher
in dialysis patients than in normal controls [17].
Baseline insulin levels tended to be higher in the dialysis
patients than in the controls, although this difference did not
achieve statistical significance. This observation is consistent
with previous reports, and has been attributed to insulin resis-
tance in uremic patients [25]. The changes in glucose and insulin
levels during the epinephrine infusion were similar in both
experimental groups, both in the absence and presence of beta
blockade. Epinephrine-induced hyperglycemia is primarily due
to a stimulation of glucose production (gluconeogenesis and
glycogenolysis), that is mediated by beta-adrenergic receptors
[26]. The lack of increase in plasma insulin concentrations
during epinephrine infusion, in the face of rising glucose levels,
suggests an inhibition of insulin release. This is in contrast to
the effect of the administration of pure beta-agonists, such as
albuterol, which has been associated with increases in both
plasma glucose and insulin concentrations [11, 14]. Previous
studies have demonstrated that beta-adrenergic stimulation
causes insulin release, whereas aipha-adrenergic stimulation
inhibits the release of insulin by the pancreas [27]. This alpha
effect on insulin release appears to predominate during epineph-
rifle infusion, and most likely accounts for the persistence of the
hyperglycemic response during pure aipha-adrenergic stimula-
tion (infusion of epinephrine during beta blockade). This is also
supported by the tendency of insulin levels to fall during the
second study protocol.
The observation of epinephrine-induced decrease in serum
phosphate in normal subjects is consistent with previous obser-
vations [28]. The dialysis patients in the present study were
resistent to the hypophosphatemic effect of epinephrine. The
magnitude of change in serum phosphate did not correlate
significantly with the change in serum potassium. Thus, it is not
clear that a common mechanism of resistance to the effect of
epinephrine can be applied for both ions.
The magnitude of increase in heart rate tended to be smaller
in dialysis patients than in normal controls. Since the change in
heart rate is a /3 effect, there may be a disparity between the
effects of uremia on beta-adrenergic responsiveness, with
blunted response, but a preserved /32 response.
The enhanced alpha-adrenergic responsiveness in hemodia!-
ysis patients may be of considerable clinical relevance. It may
contribute to the development of hyperkalemia in hemodialysis
patients, independently of the defect in renal potassium excre-
tion. Hemodialysis patients have impaired extrarenal disposal
of potassium following an oral potassium load [291. Thus, alpha
blockers may be efficacious in preventing hyperkalemia, while
beta blockers may promote hyperkalemia in these patients.
Since diabetic patients were excluded from the present study, it
is not known whether the conclusions of this study are appli-
cable to diabetic dialysis patients.
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